Get the Stockscreener App
14.52
4.12%
0.575
Pre-market:
14.63
0.11
+0.76%
Erasca Inc stock is traded at $14.52, with a volume of 6.27M.
It is up +4.12% in the last 24 hours and down -17.50% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
See More
Previous Close:
$13.95
Open:
$13.82
24h Volume:
6.27M
Relative Volume:
1.36
Market Cap:
$5.08B
Revenue:
-
Net Income/Loss:
$-277.02M
P/E Ratio:
-15.57
EPS:
-0.9328
Net Cash Flow:
$-91.36M
1W Performance:
-5.35%
1M Performance:
-17.50%
6M Performance:
-1.02%
1Y Performance:
+660.21%
1-Day Range:
$13.54
$15.07
1-Week Range:
$13.54
$15.78
52-Week Range:
$1.775
$24.28
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
14.52 | 5.08B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca stock gains 4.12 percent ahead of trial data - AD HOC NEWS
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Investors to Inquire about Securities Investigation - accessnewswire.com
Erasca, Inc. (ERAS) Stock Price, News, Quote & History - Yahoo! Finance Canada
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - Supply Chain Digital Magazine
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - GlobeNewswire Inc.
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION - GlobeNewswire
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Stockholders to Reach Out - ACCESS Newswire
How to buy Erasca, Inc. stock (rERAS) in Aruba? - Bitget
ERAS 8-K FilingsErasca, Inc. SEC 8-K - Stock Titan
Important Notice to Long-Term Shareholders of Aardvark - GlobeNewswire
Erasca, Inc. (NASDAQ: ERAS) foundation plans another ERAS stock sale - Stock Titan
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Erasca, Inc. (ERAS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Investors to Connect - ACCESS Newswire
Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2026. - marketscreener.com
Attention Long-Term Shareholders of Aardvark Therapeutics, - GlobeNewswire
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium - manilatimes.net
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Erasca stock holds gains as FDA Fast Track boosts cancer pipeline - ad-hoc-news.de
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage - Yahoo Finance
Erasca stock gains visibility as FDA fast tracks ERAS-0015 - ad-hoc-news.de
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Erasca Inc. (ERAS) Shares Tumble 7.5% to $18.03 as Selling Pressure MountsNew Highs New Lows - careplusvn.com
Should FDA Fast Track for ERAS-0015’s Pan-RAS Glue Require Action From Erasca (ERAS) Investors? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Stockholders to Connect - ACCESS Newswire
Erasca Receives FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Metastatic Pancreatic Cancer - Oncodaily
INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - Eastern Progress
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities LawsuitContact The Gross Law Firm - Eastern Progress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - Eastern Progress
Erasca (ERAS) Momentum: Slides 5.67% to $17.05 in the Latest Session; Immediate View: Traders Can Monitor the $16.20-$17.90 Range for the Current SessionIchimoku Kumo Twist - Vinanet
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS - MarketBeat
Law firm probes Erasca directors for possible b... - Pluang
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB - MarketBeat
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Nigeria
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - Sahm
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
Erasca (NASDAQ: ERAS) foundation to sell 8,333 shares - Stock Titan
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes - Stock Titan
ERAS Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
Bank of America Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - MarketBeat
Erasca, Inc. Stock 12‑Month Price Target Raised to $23, Implies 29% Upside - TradingView
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):